Noncontrolling Interest (Tables)

6 Months Ended

Jun. 30, 2021

Noncontrolling Interest [Abstract]

Schedule of Noncontrolling Interest of Stockholders' Equity

The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity is with respect to each of the Company’s majority-owned subsidiaries: Lucid Diagnostics Inc., Solys Diagnostics Inc., and Veris Health Inc., with the NCI summarized for the periods indicated as follows:

	Six Months Ended June 30, 2021			Year Ended December 31, 2020
NCI – equity (deficit) – beginning of period	$	(2,369	)	$	(814	)
Investment in Veris Health Inc.		6			—
Net loss attributable to NCI – Lucid Diagnostics Inc.		(1,782	)		(1,503	)
Net loss attributable to NCI – Solys Diagnostics Inc.		(22	)		(109	)
Net loss attributable to NCI – Veris Health Inc.		(73	)		—
Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise		—			5
Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan		3,329			52
NCI – equity (deficit) – end of period	$	(911	)	$	(2,369	)